Clozapine Tablet, Orally Disintegrating
FDA Label NDC 0093-5416

76 label sections · Submitted to the FDA by Teva Pharmaceuticals Usa, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Teva Pharmaceuticals Usa, Inc. for the product Clozapine (NDC 0093-5416). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: severe neutropenia; orthostatic hypotension, bradycardia, and syncope; seizure; myocarditis, pericarditis, and cardiomyopathy; increased mortality in elderly patients with dementia-related psychosis, 1.1 treatment-resistant schizophrenia, 1.2 reduction in the risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder, 2.1 absolute neutrophil count testing prior to clozapine odt initiation, 2.2 recommended dosage and administration, 2.3 dosage modifications based on anc results, 2.4 dosage modifications based on anc results for patients with benign ethnic neutropenia, 2.5 discontinuation of clozapine odt treatment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.